The investment school slows down. Analysis of the Week finds Biotech opportunities!

Take advantage of the knowledge at Vikingen!

The Summer Solstice weekend brought good weather, good food for many of us and the Investment School slows down over the summer. We will make minor corrections during the summer, but overall we will keep our trade low. See below which holdings we have now. Our free time will be focused on learning from all the knowledge available in recorded form on the Vikingen website. You can also access this information free of charge!

Here are four videos recorded by our mentor Peter Östevik on technical analysis and how to best use Viking’s various programs, from Viking Mini, to Exchange, Trading and Maxi. These four films contain incredibly valuable information.
The films are in Swedish. The most purchased Vikingen program is Vikingen Exchange, which you can purchase here.
Or why not take advantage of our summer offer until June 30th and get a 25% discount on Vikingen Trading. The code is WIKNOW2024

Here are 20 short, educational films by Uffe Raahede. The videos provide you with the information you need to get started with technical analysis and Vikingen. The films are in Danish. On the same page where you can find Uffe Raahede’s videos, there is also a webinar with Lars Persson, called “Vikingen Basic Course” .

Below is the “Analysis of the Week with Stock Tips” from Bjørn Inge Pettersen of StockCharts365. Today, has taken a closer look at a very interesting Swedish biotech company .

Investment school holdings week 26

Hexatronic (HTRO), we choose to keep. The stock has declined in the last week but is showing good long-term performance in the Vikingen and has risen since we bought.
The BankNordik P/F share has been very still but has gone up last week and today a little more. We have placed a sales order on this stock at a level where we make a small profit.
Per Aarsleff Holding we are keeping this well-managed company which still shows a good forecast ahead and where we made a small nice profit.
Bergman & Beving Aktiebolag, ser B A well-managed company that is now expanding its purchasing strategy. We have made a small profit on this stock and choose to recoup it now. The shares we sell we put on our watch list, we think Bergman & Beving is still interesting.
MPC Container Ships a Norwegian share that we choose to keep. They have very high occupancy rates on their ships and the stock only seems to go in one direction, up!
BULL NVIDIA X5 NORDNET 1 we sold at the end of last week when the stock started to go down, which we are happy about. We have put some effort into BULL GOLD X8 NORDNET. Gold is going up so we hope that this purchase will be favorable.

We choose later this afternoon to buy BioInvent (see Analysis of the Week below by for the funds we made available through the above sales. And we buy two more shares that Vikingens Återförsäljare in Denmark finds interesting(Lars Persson). Both look great and are safe investments for the longer term now that we want to be less active during the summer!

Alk Abello B A/S , which develops and sells pharmaceuticals at a global level in the field of allergy and immunotherapy. The products are sold both as vaccines and in tablet form.
Svitzer Group A/S is a Danish shipping company. Its core business consists of providing towing and assistance services to seagoing vessels to maneuver in and out of ports and terminals.

That was this week’s investment school. Feel free to give us feedback and follow us on FB and/or Linkedin. We look forward to your contact!

A Swedish, interesting biotech company

StockCharts365. com has this week taken a closer look atBioInvent International AB (Ticker on Nasdaq Stockholm: BINV). is not alone in its belief in this stock, and the stock is included in Pareto’s Swedish equity portfolio, and recently on June 7, Van Lanschot Kempen (Kempen) reiterated its Buy recommendation on BioInvent and raised its price target for the stock to SEK 55 (from SEK 30 previously).

Briefly about the company BioInvent (BINV)

BioInvent is a clinical-stage biotechnology company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase I/II trials for the treatment of hematological cancers and solid tumors and a fifth program just entering clinical development.

BioInvent’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates, to drive the company’s own clinical development pipeline or for further licensing and partnering.

BioInvent generates revenue from research collaborations and licensing agreements with several top-tier pharmaceutical companies, as well as from producing antibodies for third parties in its fully integrated manufacturing unit. The head office is located in Lund, Sweden.

For more information about BioInvent (BINV) visit their website:

Technical analysis of BioInvent (BINV)

The BioInvent stock is showing strong performance within a sharply rising trend and further growth is signaled for the stock in both the short and medium term. The stock is consolidating in the very short term after breaking above an important technical resistance level around 32.00 SEK (cf weekly chart). The stock is now consolidating between SEK 32.00 and SEK 38.00 and StockCharts365. com believes that a breakout from this consolidation formation could come soon.

This will trigger a new technical buy signal for the stock. Various momentum indicators like RSI and Stochastics indicate that the stock could face further upside in the near term. On the upside, there is therefore some technical resistance around the SEK 38.00 level, but then there will be little technical resistance until up to the SEK 50.00 level. On the downside, there is significant technical support around the SEK 32.00 level and around the 50-day moving average at the SEK 30.00 level.

BEST The model gives a buy signal

The BEST model also now gives a buy signal for BioInvent (BINV). This popular and effective model was developed by Peter Östevik. He finalized the model around 2019 after 30 years of experience in technical analysis and Vikingen. The overall technical pictureThe outlook for BioInvent shares is therefore positive and further growth is signaled for the stock in both the short and medium term. StockCharts365. com sees a short-term (1-3 months) potential for the stock of around SEK 50.00.

Leave a Reply

Your email address will not be published. Required fields are marked *